2183.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 02:15):

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide...

Stats
Today's Volume	15 600.00
Average Volume	104 557
Market Cap	8.99B
EPS	¥0 ( 2024-02-13 )
Next earnings date	( ¥0 ) 2024-05-12
Last Dividend	¥14.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.21
ATR14	¥1.010 (0.25%)

Volume Correlation

Long: -0.13 (neutral)

Short: -0.48 (neutral)

Signal:(50.54) Neutral

Linical Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Linical Co., Ltd. Correlation - Currency/Commodity

-0.21
( neutral )

-0.63
( weak negative )

-0.23
( neutral )

0.19
( neutral )

0.15
( neutral )

0.80
( moderate )

Linical Co., Ltd. Financials

Annual	2022
Revenue:	¥12.52B
Gross Profit:	¥4.16B (33.25 %)
EPS:	¥44.47

Q3	2023
Revenue:	¥3.18B
Gross Profit:	¥898.35M (28.21 %)
EPS:	¥3.30

Q2	2023
Revenue:	¥2.98B
Gross Profit:	¥1.04B (34.78 %)
EPS:	¥7.76

Q1	2023
Revenue:	¥3.08B
Gross Profit:	¥947.39M (30.74 %)
EPS:	¥0.160

Financial Reports:

No articles found.

Linical Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥14.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Linical Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.08 - Decrease likely (38.37%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥3.00	2009-03-26
Last Dividend	¥14.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	¥111.75	--
Avg. Dividend % Per Year	0.00%	--
Score	2.78	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.08
Div. Directional Score	7.06	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

2.78

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9536.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8137.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7487.T	Ex Dividend Junior	2024-05-30	Annually	0.00%
6715.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6059.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
4739.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3983.T	Ex Dividend Knight	2023-12-28	Annually	0.00%
3193.T	Ex Dividend Junior	2024-01-30	Annually	0.00%
2183.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9055.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0543	1.500	8.91	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0385	1.200	8.72	10.00	[0 - 0.3]
returnOnEquityTTM	0.0876	1.500	-0.138	-0.206	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.712	0.800	6.44	5.15	[1 - 3]
quickRatioTTM	1.467	0.800	6.08	4.86	[0.8 - 2.5]
cashRatioTTM	1.018	1.500	5.46	8.19	[0.2 - 2]
debtRatioTTM	0.154	-1.500	7.43	-10.00	[0 - 0.6]
interestCoverageTTM	71.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.349	-1.500	8.60	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.324	1.000	7.93	7.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.0925	1.000	-0.151	-0.151	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.05	9.05	[0.2 - 2]
assetTurnoverTTM	0.708	0.800	8.61	6.89	[0.5 - 2]
Total Score				11.04

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.85	1.000	8.80	0	[1 - 100]
returnOnEquityTTM	0.0876	2.50	-0.0884	-0.206	[0.1 - 1.5]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.88	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.229	1.500	-4.86	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0810	1.000	-0.474	0	[0.1 - 0.5]
Total Score				3.08

Linical Co., Ltd.

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.